Cancer, Reproductive, Cardiovascular, and Other Chronic Disease Prevention Program

Program Impact

NIOSH is strongly committed to program evaluation as a way to maximize its contributions to improved occupational safety and health. Regular review of program activities, outputs, and outcomes is essential to demonstrating program performance. The CRC conducts reviews and shares program impact in a variety of ways.

Program Performance One-pager

Program Performance One-Pagers (PPOPs) are a snapshot of NIOSH programs’ priorities, strategies used to make progress towards priorities, recent accomplishments, and upcoming work.

CRC Program Performance One-pager

Impact Sheets

Impact Sheets briefly describe an occupational safety or health hazard, the specific NIOSH or NIOSH-funded research activity that was conducted to address the hazard, the resulting impact or recommendations, and relevant statistics. Selected NIOSH Impact Sheets relevant to the CRC Program are listed here:

• NIOSH Research Improves Equipment Design to Protect Firefighters
• NIOSH-funded Study Results in Improved Pesticide Testing Methods and Updated Regulations to Protect Agricultural Workers
• A NIOSH-funded Research Study Improves Safety and Health of Farm Workers and Their Families
• NIOSH-funded Research Helps Reduce Occupational Exposure to PCBs When Renovating Schools
• Data into Action: NIOSH Blood Lead Surveillance Program Contributes to a Decline in National Prevalence Rates
• NIOSH Pesticide Poisoning Monitoring Program Protects Farmworkers
• Approaches to Safe Nanotechnology: Document Provides Guidance to Protect Nanotechnology Workers
• NIOSH List of Hazardous Drugs in Healthcare Settings Allows Healthcare Workers to Minimize Exposure and Reduce Health Risks
• NIOSH Research Demonstrates the Effectiveness of No-Nose Bicycle Seats in Reducing Groin Pressure and Improving Sexual Health
• NIOSH Research Methods Demonstrate that Breathing Nanoparticles May Result in Damaging Health Effects
• Collaborative Partnerships and Products of the NIOSH Hazardous Drug Working Group
• Silica, Lung Cancer, and Respiratory Disease Quantitative Risk